[13C5]-Pomalidomide
| Product Name | [13C5]-Pomalidomide |
|---|---|
| Alternate Names | Pomalidomide Stable Isotopes, Stable Isotopes of Pomalidomide |
| CAT No. | CS-EK-01851 |
| CAS No. | 19171-19-8 unlabeled |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | Not Available |
| Mol. For. | Not Available |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Pomalidomide |
| Canonical Smiles | C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N |
| InchIKey | UVSMNLNDYGZFPF-UHFFFAOYSA-N |
| Inchl | InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) |
| IUPAC | 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
[13C5]-Pomalidomide is a drug that is used in the treatment of multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow. This drug is a derivative of thalidomide and lenalidomide, which are also used in the treatment of multiple myeloma.
The chemical formula of [13C5]-Pomalidomide is C22H18N4O4, and it has a molecular weight of 398.41 g/mol. The drug works by inhibiting the growth and proliferation of cancer cells by targeting specific proteins involved in the development of the disease.
[13C5]-Pomalidomide is administered orally, usually in the form of capsules, and is taken once daily. The dosage and duration of treatment depend on the severity of the disease and the patient's response to the drug.
The drug may cause side effects such as fatigue, nausea, and diarrhea, and it may also increase the risk of infections. Therefore, patients undergoing treatment with [13C5]-Pomalidomide should be closely monitored by their healthcare providers.
In conclusion, [13C5]-Pomalidomide is a valuable drug in the treatment of multiple myeloma and has shown promising results in clinical trials. Its chemical structure and mechanism of action make it a potent and effective drug in inhibiting cancer growth and proliferation.
![Picture of [13C5]-Pomalidomide](https://clearsynth.com/structure/-13C5--Pomalidomide.png)
Get an Instant Quote
Related Compounds
Pomalidomide D4 | Pomalidomide-15N-13C5 | Pomalidomide-13C5 | Pomalidomide D5 |